CNBX Pharmaceuticals Inc.
CNBX
$0.00
$0.00-20.00%
OTC PK
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 129.70K | 40.40K | 64.70K | 36.80K | 126.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.70K | 40.40K | 64.70K | 36.80K | 52.50K |
| Operating Income | -129.70K | -40.40K | -64.70K | -36.80K | -52.50K |
| Income Before Tax | -150.10K | -59.70K | -69.80K | -34.40K | -60.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -150.10K | -59.70K | -69.80K | -34.40K | -60.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -150.10K | -59.70K | -69.80K | -34.40K | -60.60K |
| EBIT | -129.70K | -40.40K | -64.70K | -36.80K | -52.50K |
| EBITDA | -111.70K | -22.30K | -46.70K | -18.80K | -52.50K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 256.17M | 42.60M | 32.10M | 31.11M | 31.10M |
| Average Diluted Shares Outstanding | 256.17M | 42.60M | 32.10M | 31.11M | 31.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |